The insulin and insulin-like growth factor receptor family in neoplasia: an update

By Michael Pollak. Nature Reviews. Cancer, 2012

1,090 citations recorded by the source corpus.

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

Promoting Health and Longevity through Diet: from Model Organisms to Humans (2015, neutral): “, 2009) and with the risk of developing some common cancers in humans (Pollak, 2012).”
Epidemiology of Renal Cell Carcinoma (2020, background): “While the precise pathogenesis remains unelucidated, obesity promotes resistance to insulin and insulin-like growth factor (facilitating uncontrolled tumor growth) [31], releases inflammatory cytokines, and disrupts metabolic homeostasis (such as stimulating the release of adiponectin) [32], leading”
Metformin: from mechanisms of action to therapies. (2014, background): “is the reduction of hyperinsulinemia, given prior evidence that high insulin levels can stimulate proliferation of a subset of common cancers(Pollak, 2012a).”
Obesity and cancer risk: Emerging biological mechanisms and perspectives. (2019, neutral): “anti-apoptosis, angiogenesis and lymphangiogenesis [72].”
PI3K/AKT/mTOR signaling transduction pathway and targeted therapies in cancer (2023, background): “Alterations in epidermal growth factor receptor (EGFR) [36, 37], fibroblast growth factor receptor (FGFR) [38, 39], platelet-derived growth factor receptor (PDGFR) [40, 41], vascular endothelial growth factor receptor (VEGFR) [42, 43], hepatocyte growth factor (HGF) [44, 45], leukocyte receptor tyro”
Recent advances in bone tissue engineering scaffolds (2012, background): “and eventual activation of P13K (phosphatidylinositol 3kinase) [10,11]”